Researchers reported an mRNA‑engineering approach that enhanced mesenchymal stem cells to create an allogeneic cell therapy candidate named DC‑25. The study describes mRNA modifications that improve MSC immunomodulatory functions and persistence, aiming to overcome limitations of autologous products. The work positions DC‑25 as a scalable off‑the‑shelf immunotherapy platform with potential applications in immune modulation and regenerative medicine.